Airain ltd acquired a new position in Retrophin, Inc. (NASDAQ:RTRX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 21,753 shares of the biopharmaceutical company’s stock, valued at approximately $422,000. Airain ltd owned about 0.06% of Retrophin as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also recently made changes to their positions in RTRX. SG Americas Securities LLC boosted its stake in Retrophin by 1.8% in the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock worth $158,000 after purchasing an additional 146 shares during the period. Legal & General Group Plc boosted its stake in Retrophin by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 355 shares during the period. American International Group Inc. boosted its stake in Retrophin by 7.1% in the 1st quarter. American International Group Inc. now owns 22,300 shares of the biopharmaceutical company’s stock worth $412,000 after purchasing an additional 1,475 shares during the period. Rhumbline Advisers boosted its stake in Retrophin by 4.4% in the 2nd quarter. Rhumbline Advisers now owns 47,454 shares of the biopharmaceutical company’s stock worth $920,000 after purchasing an additional 2,010 shares during the period. Finally, Credit Suisse AG boosted its stake in Retrophin by 8.4% in the 1st quarter. Credit Suisse AG now owns 57,025 shares of the biopharmaceutical company’s stock worth $1,052,000 after purchasing an additional 4,407 shares during the period.
TRADEMARK VIOLATION WARNING: “Airain ltd Acquires New Position in Retrophin, Inc. (RTRX)” was originally reported by BBNS and is the property of of BBNS. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://baseballnewssource.com/markets/airain-ltd-purchases-shares-of-21753-retrophin-inc-rtrx/1588520.html.
In other Retrophin news, COO Neil F. Mcfarlane sold 1,378 shares of the company’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $22.50, for a total value of $31,005.00. Following the completion of the sale, the chief operating officer now owns 13,622 shares in the company, valued at $306,495. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 2.41% of the company’s stock.
Shares of Retrophin, Inc. (NASDAQ:RTRX) traded down 0.18% during mid-day trading on Thursday, hitting $22.70. The stock had a trading volume of 202,500 shares. The stock’s 50-day moving average is $22.97 and its 200 day moving average is $19.66. Retrophin, Inc. has a 12 month low of $15.55 and a 12 month high of $25.11. The company’s market cap is $871.34 million.
Retrophin (NASDAQ:RTRX) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). The company had revenue of $38.80 million during the quarter, compared to analysts’ expectations of $37.36 million. Retrophin had a negative return on equity of 7.31% and a negative net margin of 48.74%. The business’s quarterly revenue was up 16.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.07 EPS. On average, equities research analysts forecast that Retrophin, Inc. will post ($1.13) earnings per share for the current fiscal year.
Several research analysts have commented on RTRX shares. ValuEngine downgraded Retrophin from a “hold” rating to a “sell” rating in a research note on Friday, June 2nd. BidaskClub upgraded Retrophin from a “hold” rating to a “buy” rating in a research note on Wednesday, August 16th. Two analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $32.33.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with our FREE daily email newsletter.